Piper Jaffray Companies reissued their buy rating on shares of Xencor, Inc. (NASDAQ:XNCR) in a research note published on Sunday. Piper Jaffray Companies currently has a $35.00 target price on the biopharmaceutical company’s stock.

XNCR has been the subject of a number of other research reports. Canaccord Genuity set a $36.00 price objective on shares of Xencor and gave the company a buy rating in a research report on Monday, October 23rd. BidaskClub downgraded shares of Xencor from a hold rating to a sell rating in a research report on Monday, August 14th. ValuEngine upgraded shares of Xencor from a sell rating to a hold rating in a research report on Friday, September 1st. Finally, Zacks Investment Research downgraded shares of Xencor from a hold rating to a sell rating in a research report on Saturday. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $30.25.

Shares of Xencor (NASDAQ XNCR) traded up $1.07 during trading hours on Friday, reaching $21.03. 146,300 shares of the company were exchanged, compared to its average volume of 165,828. Xencor has a 1 year low of $18.55 and a 1 year high of $29.38.

TRADEMARK VIOLATION WARNING: “Xencor’s (XNCR) Buy Rating Reaffirmed at Piper Jaffray Companies” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/13/xencors-xncr-buy-rating-reaffirmed-at-piper-jaffray-companies.html.

In related news, major shareholder John S. Stafford III purchased 43,500 shares of Xencor stock in a transaction dated Friday, August 18th. The stock was bought at an average cost of $19.93 per share, for a total transaction of $866,955.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder John S. Stafford III purchased 79,035 shares of Xencor stock in a transaction dated Thursday, August 17th. The shares were bought at an average price of $20.47 per share, with a total value of $1,617,846.45. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 430,933 shares of company stock valued at $8,611,759. Insiders own 4.14% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Alps Advisors Inc. increased its stake in shares of Xencor by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 20,102 shares of the biopharmaceutical company’s stock worth $424,000 after purchasing an additional 52 shares in the last quarter. Falcon Point Capital LLC increased its stake in shares of Xencor by 0.5% during the 2nd quarter. Falcon Point Capital LLC now owns 29,082 shares of the biopharmaceutical company’s stock worth $614,000 after purchasing an additional 156 shares in the last quarter. Parametric Portfolio Associates LLC increased its stake in shares of Xencor by 0.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 36,253 shares of the biopharmaceutical company’s stock worth $867,000 after purchasing an additional 209 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Xencor by 4.5% during the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 385 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. increased its stake in shares of Xencor by 2.3% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 23,321 shares of the biopharmaceutical company’s stock worth $492,000 after purchasing an additional 521 shares in the last quarter. 76.70% of the stock is owned by institutional investors and hedge funds.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Stock Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related stocks with our FREE daily email newsletter.